A phase 1b study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with pretreated advanced gastric cancer [0.03%]
阿洛法尼布治疗经治晚期胃癌的Ⅰb期研究
Ilya Tsimafeyeu,Galina Statsenko,Liubov Vladimirova et al.
Ilya Tsimafeyeu et al.
Alofanib is a small-molecule allosteric extracellular FGFR2 inhibitor. We report safety and preliminary efficacy from the first-in-human phase 1b study of alofanib in heavily pretreated patients with advanced gastric cancer. The standard do...
Effective anticancer agents based-on two Pillar[5]arene derivatives for pancreas cancer cell lines: synthesis, apoptotic effect, caspase pathway [0.03%]
基于两种柱芳烃衍生物的抗胰腺癌有效药物：合成，凋亡效应，半胱天冬酶途径
Mehmet Ali Karaselek,Serkan Kuccukturk,Tugce Duran et al.
Mehmet Ali Karaselek et al.
This study aimed to evaluate the possible anticancer effects of two different pillar[5]arene derivatives (5Q-[P5] and 10Q-P[5]) on two different pancreatic cancer cell lines in vitro. For this purpose, changes in the expression of major gen...
A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies [0.03%]
一种肿瘤选择性腺病毒载体平台在一期临床研究中诱导产生非持久的抗磷脂抗体，不会增加血栓风险
Danny N Khalil,Isabel Prieto González-Albo,Lee Rosen et al.
Danny N Khalil et al.
Tumor-selective viruses are a novel therapeutic approach for treating cancer. Tumor-Specific Immuno Gene Therapy (T-SIGn) vectors are tumor-selective adenoviral vectors designed to express immunomodulatory transgenes. Prolonged activated pa...
Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study [0.03%]
AXL激酶抑制剂DS-1205c联合奥希替尼治疗转移性或不可切除的EGFR突变型非小细胞肺癌的疗效：一项多中心、开放标签I期临床试验结果
James Chih-Hsin Yang,Wu-Chou Su,Chao-Hua Chiu et al.
James Chih-Hsin Yang et al.
The objective of this study was to evaluate the safety and tolerability of DS-1205c, an oral AXL-receptor inhibitor, in combination with osimertinib in metastatic or unresectable EFGR-mutant non-small cell lung cancer (NSCLC) patients who d...
A phase I dose-escalation study of SYHA1813, a VEGFR and CSF1R inhibitor, in patients with recurrent High-Grade Gliomas or Advanced Solid Tumors [0.03%]
SYHA1813（一种VEGFR和CSF1R抑制剂）Ⅰ期剂量递增研究：针对复发性高级别胶质瘤或晚期实体肿瘤患者
Zhuang Kang,Shenglan Li,Yi Lin et al.
Zhuang Kang et al.
SYHA1813 is a potent multikinase inhibitor that targets vascular endothelial growth factor receptors (VEGFRs)/colony-stimulating factor 1 receptor (CSF1R). This study aimed to evaluate the safety, pharmacokinetics (PK), and antitumor activi...
Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors [0.03%]
一项I期研究，以确定自体PBMCs（携带HPV16抗原[SQZ-PBMC-HPV]）在HLA-A*02+型HPV16阳性实体瘤患者中给药的安全性及剂量上限
Antonio Jimeno,Joaquina Baranda,Wade T Iams et al.
Antonio Jimeno et al.
We conducted a dose escalation Phase 1 study of autologous PBMCs loaded by microfluidic squeezing (Cell Squeeze® technology) with HPV16 E6 and E7 antigens (SQZ-PBMC-HPV), in HLA-A*02+ patients with advanced/metastatic HPV16+ cancers. Precl...
In vitro effects of gamma-secretase inhibition in HPV-positive and HPV-negative head and neck squamous cell carcinoma [0.03%]
HPV阳性和HPV阴性头颈鳞癌中γ-分泌酶抑制的体外效应
Sara Varatanovic,Tobias Maier,Sega Al-Gboore et al.
Sara Varatanovic et al.
Background: New chemotherapy agents are warranted for head and neck squamous cell carcinoma (HNSCC), particularly for incidence-rising HPV-positive tumors. Based on the evidence of Notch pathway involvement in cancer prom...
Effect of a moderate CYP3A inducer efavirenz on the pharmacokinetics of fuzuloparib: An open-label, fixed sequence study in Chinese healthy male subjects [0.03%]
一种中等CYP3A诱导剂利福拉韦对氟唑帕利药代动力学的影响：中国健康男性受试者中的开放性、固定次序试验
Linlin Hu,Ting Dou,Qiuyue Sun et al.
Linlin Hu et al.
To evaluate the potential drug-drug interaction (DDI), safety and tolerability of fuzuloparib co-administered with a moderate CYP3A inducer efavirenz in healthy male subjects. Eighteen healthy male subjects were enrolled in a single-center,...
Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study [0.03%]
利沙万布林作为48小时输注治疗卵巢癌或复发性胶质母细胞瘤患者的安全性和抗肿瘤活性：一项2a期研究
Markus Joerger,Thomas Hundsberger,Simon Haefliger et al.
Markus Joerger et al.
Lisavanbulin (BAL101553) is the prodrug of avanbulin (BAL27862), a microtubule-destabilizing agent. The goal of this study (NCT02895360) was to characterize the safety, tolerability and antitumor activity of lisavanbulin administered as a 4...
Cyclin-dependent kinase (CDK) 4/6 inhibition in non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations [0.03%]
表皮生长因子受体突变的非小细胞肺癌中的周期素依赖性激酶4/6抑制作用
Atsushi Osoegawa,Yohei Takumi,Takafumi Hashimoto et al.
Atsushi Osoegawa et al.
Background: Lung cancer is the leading cause of cancer death worldwide, and EGFR mutation is the most common genetic alteration among Asian patients with lung adenocarcinoma. While osimertinib has been shown to be effecti...